相关实验视频

Updated: Jul 10, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

淋巴瘤后第二次原发性恶性瘤的发病率和死亡率:基于人口的分析

Yingyue Liu¹, Yurou Chu¹, Jiarui Liu²

¹Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.

Annals of medicine

|November 27, 2023

概括

第二次原发性恶性瘤 (SPMs) 在淋巴瘤幸存者中越来越多地被诊断出来,特别是老年男性. 这些二次癌症显著增加死亡风险,需要集中监测和改善患者预后.

科学领域:

在瘤学瘤学.
癌症流行病学癌症流行病学
临床研究临床研究

背景情况:

二次原发性恶性瘤 (SPMs) 在癌症存活率方面构成了越来越大的挑战.
淋巴瘤幸存者面临着发展SPM的风险越来越高,这会影响长期的结果.

研究的目的:

为了估计发病率,确定风险因素,并分析淋巴瘤幸存者的SPMs的结果.
用机构和基于人口的数据量化SPM的风险和临床特征.

主要方法:

2010年至2021年间被诊断患有SPM的淋巴瘤患者的回顾性分析.
利用机构数据和监测,流行病学和最终结果 (SEER) 数据库.
计算标准化发病率 (SIR) 来评估癌症风险.

主要成果:

淋巴瘤后SPM的患病率为2.16% (63/2912例).
在男性 (2.32:1比率),老年患者 (≥60岁) 和之前接受过化疗的患者中,SPM更为常见.
消化系统 (42.86%),呼吸系统 (20.63%),泌尿系统 (12.70%) 受到影响最大;SPM显著增加了死亡风险.

结论:

淋巴瘤患者的长期存活率导致SPM的发病率上升,特别是在老年男性中.
在淋巴瘤幸存者中增加对SPM的监测至关重要.
预后因SPM类型而异,有些提供了良好的结果,而另一些,如胃和肺瘤,预后不佳.

关键词:

第二种主要恶性瘤.发生率的发生率.淋巴瘤淋巴瘤是什么有关风险因素的风险因素.幸存率幸存率生存率

更多相关视频

Detecting Anastasis In Vivo by CaspaseTracker Biosensor

Detecting Anastasis In Vivo by CaspaseTracker Biosensor

Published on: February 1, 2018

A Revised Method for Inducing Secondary Lymphedema in the Hindlimb of Mice

A Revised Method for Inducing Secondary Lymphedema in the Hindlimb of Mice

Published on: November 2, 2019

相关概念视频

Mechanisms of Retrovirus-induced Cancers

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Cancer Prevention

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...